Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Tabernero, Josep (Hospital Universitari Vall d'Hebron)
Hozak, Rebecca R. (Eli Lilly and Company, Indianapolis)
Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East (Chiba, Japó))
Cohn, Allen Lee (Rocky Mountain Cancer Center/US Oncology (Denver, Estats Units d'Amèrica))
Obermannova, Radka Lordick (Masaryk Memorial Cancer Institute (Brno, República Txeca))
Bodoky, György (St László Hospital (Hongria))
García-Carbonero, Rocío (Universidad Complutense de Madrid)
Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology (Cluj-Napoca, Romania))
Portnoy, David C. (Oncology, West Clinic (Memphis, Estats Units d'Amèrica))
Prausová, Jana (University Hospital Motol (Praga, República Txeca))
Muro, Kei (Aichi Cancer Center Hospital (Nagoya, Japó))
Siegel, Robert (Eli Lilly and Company (Indianapolis, Estats Units d'Amèrica))
Konrad, Robert John (Eli Lilly and Company (Indianapolis, Estats Units d'Amèrica))
Ouyang, H. (Eli Lilly and Company, Indianapolis)
Melemed, Symantha A. (Eli Lilly and Company, Indianapolis)
Ferry, David R. (Eli Lilly and Company, Indianapolis)
Nasroulah, Federico (Eli Lilly and Company, Indianapolis)
Van Cutsem, Eric (Katholieke Universiteit te Leuven (1970-))
Universitat Autònoma de Barcelona

Data:	2017
Resum:	The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes. Plasma and tumor tissue collection was mandatory. Overall, 1072 patients were randomized 1 : 1 to the addition of ramucirumab or placebo to FOLFIRI chemotherapy. Patients were then randomized 1 : 2, for the biomarker program, to marker exploratory (ME) and marker confirmatory (MC) groups. Analyses were carried out using exploratory assays to assess the correlations of baseline marker levels [VEGF-C, VEGF-D, sVEGFR-1, sVEGFR-2, sVEGFR-3 (plasma), and VEGFR-2 (tumor tissue)] with clinical outcomes. Cox regression analyses were carried out for each candidate biomarker with stratification factor adjustment. Biomarker results were available from.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Ramucirumab ; Colorectal cancer ; VEGF-D ; Viomarkers ; Predictive
Publicat a:	Annals of oncology, Vol. 29 (december 2017) , p. 602-609, ISSN 1569-8041

DOI: 10.1093/annonc/mdx767
PMID: 29228087

8 p, 590.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats